Financial Giant Citi Predicts Stablecoin Market Cap Could Balloon to $4,000,000,000,000 in Just Five Years
The financial services giant Citi foresees explosive growth for the stablecoin market by the end of the decade.
Stablecoins are digital assets backed by high-quality short-term securities or cash-like assets that operate on blockchains.
In a new report , Citi says that in a best case scenario, the total market cap of stablecoins will surge to $4.0 trillion in the next five years.
“We are revising our stablecoin total issuance forecasts in this report to: $1.9 trillion base case (previously $1.6 trillion) and $4.0 trillion bull case ($3.7 trillion), due to the strong growth of the market in the past six months and the wide range of project announcements, in the U.S. and internationally.”
The bank says it is raising its original forecast in its April 2025 Citi GPS: Digital Dollars report because of the strong momentum in the ecosystem, which includes the integration by payment networks, launch of new layer-1 blockchains and regulatory clarity in key markets.
The report says the issuance volumes of the nascent asset grew by over 20% in the past six months and nearly 40% year-to-date.
During this period, US legislators passed the GENIUS Act to establish a regulatory framework for stablecoins. The European Union also began the enforcement of the Markets in Crypto-Assets Regulation (MiCAR) that covers electronic money tokens and Hong Kong introduced licensing rules for stablecoins.
“Summer 2025 has been dubbed ‘Stablecoin Summer’ by industry participants. New business activity around stablecoins, for solutions including commerce, payments and ‘real world’ applications, have heated up over the summer. We believe these could further power issuance and transaction volumes during 2026 and beyond.”
Generated Image: Midjourney
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Bitcoin Updates: ETF Withdrawals and Rising Short Positions Push Bitcoin Below Bearish Threshold
- Bitcoin fell below the 0.75 cost basis quantile, a key bear-market threshold identified by Glassnode, signaling renewed downward pressure. - ETF outflows surged $866.7M on November 13, with BlackRock's IBIT and Grayscale's Bitcoin Mini Trust leading redemptions amid $100,000 price drop. - Harvard's $443M IBIT investment contrasts with bearish technical signals like the "death cross," while Nansen tracks $5.7M in new short positions. - Tight futures liquidity and 46% Fed rate-cut probability amplify downs
Bitcoin Updates Today: Is Crypto's Death Cross Indicating a Recovery or Warning of a Downturn?
- Cryptocurrency markets face selloff as Bitcoin , Ethereum , and XRP decline amid a "death cross" signal and waning institutional demand. - Technical analysis highlights Bitcoin's 50-day moving average nearing the 200-day line, historically linked to prolonged downturns or potential rebounds. - Blockchain data reveals $953M BTC moved from Mt. Gox wallets, triggering $1B in forced liquidations despite analysts labeling the transfers administrative. - Historical death crosses have preceded market bottoms, b
Aster News Today: DeFi Competition Heats Up: Incentivizing Liquidations to Draw in Traders
- Aster, a decentralized crypto exchange, launched "Machi mode" to reward traders with points for liquidations, embracing risk-taking culture. - Competitor Hyperliquid slashed taker fees by 90% via HIP-3 "growth mode," targeting liquidity providers and challenging centralized exchanges. - Both strategies reflect DeFi's arms race to attract traders through gamification (Aster) and technical efficiency (Hyperliquid), blurring financial utility with community identity. - Traders praised Aster's "failure-as-fe
Olema’s Proposal Dampens Hopes for Trial, Sparks Decline Due to Dilution Concerns
- Olema Pharmaceuticals (OLMA) shares fell 6.9-7.2% post-announcement of a stock and warrant offering, triggering dilution concerns among investors. - The TD Cowen-led offering includes a 30-day greenshoe option for up to 15% additional shares, with proceeds intended to fund breast cancer therapies like palazestrant (Phase 3) and OP-3136 (Phase 1). - Despite recent 81% stock gains and positive SERD trial data from Roche, the offering overshadowed optimism, though analysts at H.C. Wainwright and Guggenheim
Trending news
MoreCrypto prices
More
